Of note, Jiang et al.12 recently showed that miR-150 inhibits MLL/AF9-mediated leukemia transformation through targeting MYB and FLT3. Another groups identified CBL and EGR2 as bona fide targets of miR-150 in MLL/AF9-transformed leukemia,13 and loss of CBL sensitizes leukemia to chemotherapy.20 The differences between our findings and the previous reports could be explained in part by the differences in genetic backgrounds and methodologies used. The gene discussed is CBL; the disease is leukemia.